Clinical trials: Influenza Type A
Influenza, Virus Diseases
Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine
In the 20th century, influenza pandemics occurred in 1918, 1957, and 1968, and were associated with significant morbidity and mortality.
- Trial name
- NCT00734175
- Testing
- H6N1 Teal HK 97/AA ca recombinant vaccine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Avian Influenza, H1N1 Influenza
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
This is a single center, randomized, partially-blinded, Phase II, small, targeted, prospective study in approximately 30 healthy male and non-pregnant female subjects aged 18 to 49 years old, inclusive, designed to evaluate and…
- Conditions
- Avian Influenza, H1N1 Influenza, Influenza
- Trial name
- NCT02921997
- Testing
- AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
H5N1 Mix and Match With AS03
Approximately 216, and up to 240, healthy males and non-pregnant females, 18 to 49 years old, inclusive, will be enrolled over a 5-month period into this multicenter, randomized, double-blinded, controlled Phase I study.
- Trial name
- NCT01317758
- Testing
- AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen
- Where
- 4 sites in United States
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
A Phase 2 Randomized, Placebo- and Active-Controlled, Human Influenza A/California/04/2009 (H1N1) Challenge Study Following Administration of an Oral H1N1 Hemagglutinin (HA) Adenoviral-Vector Based Seasonal Influenza Vaccine and…
- Trial name
- NCT02918006
- Testing
- VXA-A1.1, Fluzone®
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Vaxart
Diphtheria, Tetanus
Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks
A multicenter, observational study to evaluate the safety of Euforvac-Hib vaccine for active primary immunization against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza type B in infants.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT02257645
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Influenza, Influenza, Human
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
The purpose of this study is to evaluate the body's immune response at different time points to an FDA-approved seasonal influenza vaccine.
- Conditions
- Influenza, Influenza, Human, Vaccine Reaction, Influenza A
- Trial name
- KIRV (NCT03743688)
- Testing
- Influenza Vaccine Recipients
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Influenza, Human
Jet Injection for Influenza
The purpose of this study is to determine if the administration of a seasonal flu vaccine using a PharmaJet's needle-free injection device (STRATIS) is equivalent to needle and syringe administration, as measured by laboratory…
- Trial name
- JIFI (NCT01688921)
- Testing
- AFLURIA vaccine (2012-2013 formulation), Needle-Syringe, Stratis needle-free injection device
- Where
- 3 sites in United States
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- PharmaJet, Inc.
Influenza A Virus Infection
Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza
In recent years, influenza viruses that have traditionally infected animals have infected humans as well. The H2N3 influenza virus, which first appeared in pigs in the Midwest United States in 2006, may pose a potential health…
- Trial name
- NCT01175122
- Testing
- H2N3 MO 2003/AA ca Vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
Dose Finding Study of Single Dose GHB11L1 in Healthy Adults
The purpose of this phase IIa trial is to evaluate the immunogenicity of a single dose of GHB11L1 administered by liquid nasal spray for vaccination against influenza A (H1N1) virus.
- Trial name
- GHB-CS07 (NCT01078701)
- Testing
- GHB11L1
- Where
- Austria
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Influenza A
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
This is a Phase I double-blind, randomized, placebo-controlled study in 250 healthy adults, 18-49 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03999554
- Testing
- LD Sing2016 M2SR H3N2 influenza vaccine, MD Sing2016 M2SR H3N2 influenza vaccine, HD Sing2016 M2SR H3N2 influenza vaccine
- Where
- 4 sites in United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Influenza
Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®
To describe the safety findings from Days 0 to 44 following injection of the 2003-2004 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule in accordance with the…
- Trial name
- NCT00836953
- Testing
- Influenza virus vaccine (Pediatric formulation)
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study
The primary objective of this observational, comparative safety study is to evaluate the safety of the Novartis Pandemic Influenza A (H1N1) vaccine in pregnant women and their off spring, followed for up to 3 months of age as…
- Trial name
- NCT01037829
- Testing
- Non-intervention observational study
- Where
- 17 sites in Argentina, Italy and 1 more
- Volunteers
- 4,529 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza
The objective of this study is to evaluate the safety of the vaccine and the immune response to the vaccine in healthy adult volunteers 65 years of age or older.
- Trial name
- AVX502-003 (NCT00706732)
- Testing
- AVX502
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AlphaVax, Inc.
Influenza A
Study of VIR-2482 in Healthy Volunteers
This is a phase 1 study in which healthy volunteers will receive VIR-2482 or placebo and will be assessed for safety, pharmacokinetics, and immunogenicity of VIR-2482 in preventing Influenza A illness.
- Trial name
- NCT04033406
- Testing
- VIR-2482
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine
Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants
The objective of this study is to describe the safety and immunogenicity of a non-adjuvanted vaccine against pandemic influenza A (H1N1)in patients with chronic and or immunocompromised disease, elderly and pregnants.
- Conditions
- Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine, Immunogenicity of Pandemic Influenza A (H1N1)Vaccine
- Trial name
- NCT01218685
- Testing
- Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS
- Where
- Brazil
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Influenza
Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants
The aim of this study is to investigate the immunogenicity and safety of the inactivated split-virion vaccine in infants.
- Trial name
- NCT01494740
- Testing
- split-virion, non-adjuvanted vaccine of 7.5 μg, split-virion, non-adjuvanted H1N1 vaccine of 15 μg, split-virion, non-adjuvanted vaccine of seasonal influenza
- Where
- China
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Lymphoma, Multiple Myeloma
Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients
Primary objective 1) To assess whether oncologic and hematologic patients develop a protective immunological response after pandemic Influenza A (H1N1) vaccine Secondary objectives 1.
- Conditions
- Lymphoma, Multiple Myeloma, Myeloproliferative Disease
- Trial name
- NCT01394640
- Testing
- Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus
- Where
- Italy
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Paolo Corradini
Seasonal Human Influenza
Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers
The purpose of this phase I trial is to evaluate safety and tolerability of GHB01L1 administered as single dose intranasal aerosol for vaccination against influenza A (H1N1) virus.
- Trial name
- GHBCS-01 (NCT00724997)
- Testing
- GHB01L1
- Where
- Austria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Haemophilus Influenzae, Haemophilus Influenzae Type a
Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine
This study is testing a vaccine designed to protect against Haemophilus influenzae type a (Hia), a bacterium that can cause serious infections.This is a phase 2 trial.
- Trial name
- NCT07743008
- Testing
- Haemophilus influenzae serotype a vaccine candidate
- Where
- 2 sites in Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- InventVacc Biologicals Inc.
Influenza A Subtype H5N1 Infection
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe…
- Trial name
- NCT00755703
- Testing
- Pandemic Influenza Vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.